pimarane: from Croton joufra; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Croton | genus | A plant genus of the family EUPHORBIACEAE. The common name of dragon's blood is also used for DRACAENA and Daemonorops (ARECACEAE). Croton tiglium is the source of CROTON OIL.[MeSH] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 9548698 |
| CHEBI ID | 36547 |
| MeSH ID | M0395958 |
| Synonym |
|---|
| pimarane |
| CHEBI:36547 |
| (2r,4as,4br,8as,10as)-2-ethyl-2,4b,8,8-tetramethyl-3,4,4a,5,6,7,8a,9,10,10a-decahydro-1h-phenanthrene |
| Q27116878 |
Pimarane diterpenes are a structurally diverse family of natural products with various biological activities and pharmacological properties.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pimarane diterpenes are a structurally diverse family of natural products with various biological activities and pharmacological properties." | ( Bioactive Pimarane-Type Diterpenes from Marine Organisms. Liu, X; Lu, X; Wang, B; Wang, X; Yu, H; Zhang, Y, 2018) | 1.6 |
| Class | Description |
|---|---|
| terpenoid fundamental parent | |
| diterpene | A C20 terpene. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (44.74) | 29.6817 |
| 2010's | 20 (52.63) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (7.89%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 35 (92.11%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||